StockData
Sonoma Pharmaceuticals, Inc. logo

Sonoma Pharmaceuticals, Inc. (SNOA) company profile

SNOANasdaqSurgical & Medical Instruments & ApparatusFiscal year ends March 31
Số liệu tài chính tới Q1 năm tài chính 2027, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 11/3082% below fair value
$0.83−0.05 (-5.21%)

Close on Nov 17, 2026Market cap $3.99MP/E –Yield –

About Sonoma Pharmaceuticals

Surgical & Medical Instruments & Apparatus, SIC 3841

Sonoma Pharmaceuticals, Inc. develops and manufactures stabilized hypochlorous acid products across six primary business channels: wound care, dermatology, eye care, podiatry, animal health care, and non-toxic surface disinfectants. Its offerings include prescription, over-the-counter, and office-dispense topical solutions, hydrogels, sprays, and cleansers designed to alleviate pain, itch, redness, and scarring while supporting skin and wound healing. The company distributes its medical device solutions directly and through commercial partners to hospitals, physicians, retail pharmacy chains, pet specialty stores, and everyday consumers.

The company operates internationally, commercializing products directly or through distribution partnerships across more than 55 countries worldwide, including the United States, Europe, Asia, and Latin America. All manufacturing activities take place at a dedicated production facility located in Zapopan, Mexico. Sonoma Pharmaceuticals maintains corporate headquarters in Boulder, Colorado, with additional operational entities based in the Netherlands.

Summary of the business section of Sonoma Pharmaceuticals's latest annual report, written by StockData.

Company profile

Company

Legal name
Sonoma Pharmaceuticals, Inc.
Founded
1999
Headquarters
Boulder, CO
Address
5445 Conestoga Court, Suite 150 80301
Phone
(800) 759-9305
Employees
250, Mar 31, 2026
Industry
Surgical & Medical Instruments & Apparatus
Incorporated in
Delaware
Fiscal year ends
March 31
Auditor
Frazier & Deeter, LLC, Nashville, Tennessee

Stock & identifiers

Ticker
SNOA
Former tickers
OCLS until Aug 16, 2021
Exchange
Nasdaq
IPO date
Jan 26, 2007
Shares outstanding
5M, Aug 6, 2026
Public float
$6.32M, Sep 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-20 reverse, Aug 30, 2024; 1-for-9 reverse, Jun 20, 2019; 1-for-5 reverse, Jun 27, 2016; 1-for-7 reverse, Apr 1, 2013
SEC CIK
1367083
CUSIP
83558L303
ISIN
US83558L3033
FIGI
BBG000M75YR0
Share class FIGI
BBG001SQ8K88
LEI
54930008C5Z4F02SWO71
EIN
68-0423298

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Poggetto John DalController15,000
Amy Moss TromblyChief Executive Officer153,586
Jerome J. DvonchChief Financial Officer84,595
Bruce ThorntonExecutive VP and COO154,411
Vanessa JacobyDirector–
John McLaughlinDirector48,728
Philippe WeigerstorferDirector22,500
Jay E. BirnbaumDirector51,659

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2026$741.12K$641.73K$411.16K$11–
FY2025$597.08K$553.87K$444.95K$11–
FY2024$726.54K$697.36K$483.06K$17–
FY2023$559.94K$509.83K$299.23K$24–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2026

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOtherTotalvs. prior year
Amy Trombly
Chief Executive Officer
$407.50K$195.00K$74.88K$63.74K$741.12K+24%
Jerry Dvonch
Chief Financial Officer
$240.00K$60.00K$56.68K$66.00K$422.68K+18%
Bruce Thornton
Former Executive Vice President and Chief Operating Officer
$170.50K$156.48K$38.48K$34.18K$399.64K-25%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jan 26, 2007
Offer price
$8.00
Securities offered
3,025,000
Gross proceeds
$24.20M
Exchange
Nasdaq
First trading day
Jan 25, 2007
First-day close
$7.80-2.5%
Lock-up ends (est.)
Jul 24, 2007

“Per Share Total Public offering price $ 8.00 $ 24,200,000 Underwriting discount $ 0.56 $ 1,694,000 Proceeds, before expenses, to Oculus Innovative Sciences, Inc.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“Additionally, we had approximately 250 employees in Mexico.”

Corporate history

Events identified from SEC filings

DateEventDetails
Mar 22, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Sep 28, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jun 29, 2022Late filingNotification of late filing
Jul 20, 2021Auditor changeChange in certifying accountant (8-K Item 4.01)
Jul 9, 2021Auditor changeChange in certifying accountant (8-K Item 4.01)
Jun 29, 2021Late filingNotification of late filing
Nov 16, 2020Late filingNotification of late filing
Jun 29, 2020Late filingNotification of late filing
Jun 29, 2020Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jan 22, 2020DelistingNotice of delisting from exchange (Form 25)
Jan 8, 2019Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Feb 14, 2017Late filingNotification of late filing
Dec 2, 2016Name changeName changed from Oculus Innovative Sciences, Inc. to Sonoma Pharmaceuticals, Inc.
Nov 15, 2016Late filingNotification of late filing
Oct 31, 2016Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Oct 21, 2016ListingRegistration of securities on an exchange (Form 8-A)
Mar 12, 2015Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jan 16, 2015ListingRegistration of securities on an exchange (Form 8-A)
Dec 18, 2013Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Nov 27, 2013Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Nov 14, 2013Late filingNotification of late filing
Dec 21, 2012Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jun 21, 2012Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
May 25, 2012Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Feb 10, 2012Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Nov 26, 2008Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jan 26, 2007IPOInitial public offering priced (424B4 prospectus)
Dec 15, 2006ListingRegistration of securities on an exchange (Form 8-A)

See a number that looks wrong?